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Can Human Pluripotent Stem Cell-Derived
Cardiomyocytes Advance Understanding
of Muscular Dystrophies?
Spandan Kalraa, Federica Montanarob,∗ and Chris Denninga,∗
aDepartment of Stem Cell Biology, Centre for Biomolecular Sciences, University of Nottingham, UK
bDubowitz Neuromuscular Centre, Department of Molecular Neurosciences,
University College London - Institute of Child Health, London, UK
Abstract. Muscular dystrophies (MDs) are clinically and molecularly a highly heterogeneous group of single-gene disorders
that primarily affect striated muscles. Cardiac disease is present in several MDs where it is an important contributor to morbidity
and mortality. Careful monitoring of cardiac issues is necessary but current management of cardiac involvement does not
effectively protect from disease progression and cardiac failure. There is a critical need to gain new knowledge on the diverse
molecular underpinnings of cardiac disease in MDs in order to guide cardiac treatment development and assist in reaching
a clearer consensus on cardiac disease management in the clinic. Animal models are available for the majority of MDs and
have been invaluable tools in probing disease mechanisms and in pre-clinical screens. However, there are recognized genetic,
physiological, and structural differences between human and animal hearts that impact disease progression, manifestation,
and response to pharmacological interventions. Therefore, there is a need to develop parallel human systems to model cardiac
disease in MDs. This review discusses the current status of cardiomyocytes (CMs) derived from human induced pluripotent
stem cells (hiPSC) to model cardiac disease, with a focus on Duchenne muscular dystrophy (DMD) and myotonic dystrophy
(DM1). We seek to provide a balanced view of opportunities and limitations offered by this system in elucidating disease
mechanisms pertinent to human cardiac physiology and as a platform for treatment development or refinement.
Keywords: Human embryonic stem cells, human induced pluripotent stem cells, Cas9/CRISPR genome editing,
cardiomyocytes, Duchenne muscular dystrophy (DMD), myotonic dystrophy (DM1), disease modelling, exon skipping,
gene therapy
INTRODUCTION
The muscular dystrophies (MDs) are clinically
and molecularly a highly heterogeneous group of
single-gene disorders that are characterised clinically
∗Correspondence to: Chris Denning, Department of Stem Cell
Biology, Centre for Biomolecular Sciences, University of Notting-
ham, NG7 2RD, UK. E-mail: chris.denning@nottingham.ac.uk
and Federica Montanaro, Dubowitz Neuromuscular Centre,
Department of Molecular Neurosciences, University College Lon-
don - Institute of Child Health, London, WC1N 1EH, UK. E-mail:
f.montanaro@ucl.ac.uk.
by progressive skeletal muscle weakness and wast-
ing [1]. Transmission is usually by inheritance but
de novo mutations are common, making it impos-
sible to fully eradicate the disease. The study of
disease mechanisms and treatment development has
primarily focused on skeletal muscles with the goal
of preserving patient mobility and preventing respi-
ratory failure. However, cardiac disease is present
in several MDs (Table 1) and has emerged as an
increasingly important contributor to morbidity and
mortality [2, 3]. Current guidelines for management
of cardiac disease in MDs highlight the importance
ISSN 2214-3599/16/$35.00 © 2016 – IOS Press and the authors. All rights reserved
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of careful monitoring and tend to favour early inter-
vention with cardio-protective drugs or pacemakers,
sometimes even before patients become symptomatic
[4]. However, a clear consensus on management of
cardiac involvement and timing of treatment has not
been recognised. Furthermore, current interventions
are insufficient to prevent cardiac failure and are not
effective in all patients. Molecular processes underly-
ing cardiac disease in MDs are not fully understood,
and a current challenge is to determine whether
promising therapeutics can translate from skeletal
to cardiac muscle. The biology of these muscles is
very different regarding physical, mechanical and
signalling mechanisms. Notably, there is often no cor-
relation between the severity, or even presence, of
disease between cardiac and skeletal muscles [4–7],
suggesting different underlying disease mechanisms
exist between tissue types.
Several reviews summarize [8] our current under-
standing of disease mechanisms and responses to
various treatments that have been derived from ani-
mal models of MDs [9–14]. However, in the case
of cardiac physiology and pharmacology, there are
known differences between humans and animals.
Therefore, there is a critical need to develop human-
based platforms to study cardiac disease mechanisms
and treatment responses relevant to the human heart.
In this review, we specifically focus on the current sta-
tus and future potential of human induced pluripotent
stem cells (hiPSCs) and their differentiation into car-
diomyocytes (CMs) to further our understanding of
human cardiac disease mechanisms in MDs, and as a
platform for new treatment development. Among all
MDs with cardiac involvement, hiPSC derived CMs
(hiPSC-CMs) have been generated for Duchenne
muscular dystrophy (DMD) and myotonic dystro-
phy type 1 (DM1). DMD and DM1 are also excellent
examples of the two different major manifestations of
cardiac involvement in MDs: Dilated cardiomyopa-
thy (DCM) and conduction system disease (CSD),
respectively. These two modalities of cardiac disease
present different challenges and opportunities rela-
tive to hiPSC modelling, which will be discussed in
detail later.
Why develop hiPSC-based model system?
Differences in cardiac physiology between
animals and humans
Animal models have been generated for most MDs
and have been instrumental in our understanding of
cardiac disease in MDs. However, there are instances
where animal models do not faithfully replicate the
severity of cardiac disease seen in patients. For exam-
ple, the mdx mouse, the most commonly used animal
model for DMD, develops mild cardiac disease only
late in life and has a near normal lifespan [13]. By
contrast, cardiac involvement begins very early in
DMD patients (17% of patients are already affected
before 10 years of age [15]) and is a major contribu-
tor to early death. In other instances, animal models
are not genetic equivalents to the human condition
because introduction of the human mutation alone
does not cause disease or is genetically unstable. For
example, modelling DM1 cardiac disease in lower
organisms (C. elegans, Drosophila) or mice requires
supra-physiological expression levels or longer triple
repeat tracts to cause disease [16, 17]. Furthermore,
the repeat expansion is unstable in mice and under-
goes a reduction instead of further expansion from
one generation to the next, which is the opposite to
the human condition [17].
Additionally, differences in the structure and phys-
iology of the heart between species have an important
bearing on how this organ responds to genetic muta-
tions and to applied treatments. This is particularly
highlighted in the mouse [18], the animal model
most readily available to study MDs. The beat rate of
the mouse heart is ∼10 times faster than in humans
(500bpm vs 60bpm) and the electrocardiogram dura-
tion is 5–10 times shorter (50–100 ms in the mouse
versus 450 ms in humans). While an increase in heart
rate is associated with increased force of contraction
in humans, it is associated with decreased force in
mice [19]. The ion channels that regulate repolarisa-
tion of the CM plasma membrane are also different
between mice and humans. In mice, CM repolarisa-
tion is driven primarily by Ito, IK,slow1, IK,slow2, ISS
ion channels, while in humans this role is achieved
by the potassium channels, IKr and IKr [20]. Dif-
ferences also exist in the expression of structural
genes both during development and in the mature
heart. Developmental myosin light chains, MLC2a
and MLC2v are differentially expressed and localized
during development between rodents and humans
[21]. In the mature human heart, expression of alpha
and beta myosin heavy chains (-/-MHC) locates
to the atria and ventricles, respectively, but in the
mouse MHC is expressed in both locations [21, 22].
Phospholamban, a key regulator of intracellular cal-
cium concentration during contraction plays different
roles in mice and humans [21, 23]. A greater com-
plexity of alternative splicing has been reported in
humans relative to rodents [24], and appears to
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underlie some of the observed differences in phar-
macological properties [25], cardiac contractility and
disease progression [26, 27]. These inter-species dif-
ferences have important implications not only for
cardiac mechanics and response to disease, but also
for drug responses and toxicology. For example,
mice are at least ten times more tolerant to 37% of
drugs than humans. Issues extend to rats and dogs,
that tolerate 4.5- to 100-fold the concentration of
various chemotherapeutic agents than humans (e.g.
ThioTEPA, Myleran, Actinomycin-D, Mitomycin C,
Mithramycin, Fludarabine) [28]. Therefore, animal
models are an imperfect correlate of human cardiac
disease and, most important for development of new
treatments, they are often poor predictors of drug
efficacy, dosing and toxicology in humans.
Advantages of hiPSCs relative to other sources
of human CMs
Ideally, the existing animal model systems would
be complemented by a source of human CMs har-
bouring patient-relevant mutations. This has been
achieved for skeletal muscle by taking muscle biop-
sies. Cardiac biopsies are not taken from MD patients
because removing heart tissue is high risk and lacks
direct benefit to the patient since diagnosis can be
achieved by less invasive routes (e.g. skeletal muscle
biopsy or blood sample). Studies on cardiac biopsies
or isolated primary human CMs primarily rely on tis-
sue obtained from transplants that, by virtue, is from
the end-stage failing heart and may not be represen-
tative of the early pathological changes that occur
in CMs. Alternative indirect sources of human CMs
include trans-differentiation of human skin fibrob-
lasts using combinations of the transcription factors
GATA4, TBX5 and MEF2C. However, the efficiency
(1–25%) is too low to be useful [29–31]. Thus, cur-
rently, the most realistic way to generate human CMs
from a broad range of genotypes relevant to the mus-
cular dystrophies is via differentiation from hiPSCs.
hiPSCs can be generated from various sources
using minimally-invasive procedures. Examples
include fibroblasts isolated from skin biopsies or stem
cells isolated from urine (most likely of glomeru-
lar parietal epithelial origin) [32–34]. As a result,
both patients and healthy controls tend to be willing
to donate cells for banking to be used for diagnos-
tic and research purposes. The initial inefficiencies
in hiPSC reprogramming and hiPSC-CM differenti-
ation methods that hindered progress have now been
overcome by stepwise improvements in the technolo-
gies available. For example, non-integrating methods
approaches have replaced integrating retrovirus [34]
to improve hiPSC reprogramming efficiencies by 44-
fold from 0.1% to ∼4.4% [35].
Improvements in the methods that underpin hiPSC
technologies are allowing considerable expansion of
the range of patient mutations that can be modelled.
It is now conceivable that a reasonable proportion
of the >7000 documented mutations reported for
the DMD gene [36] could be modelled in hiPSC,
something that is not realistic in animal models.
Indeed, large scale banking schemes including
Human Induced Pluripotent Stem Cells Initiative
(HIPSCI), StemBANCC/IMI, California Institute for
Regenerative Medicine and New York Stem Cell
Foundation will create hiPSC lines from 7,000
normal or diseased skin biopsy donors using Sendai-
virus, episomes or mRNA with a combination of
SOX2, c-MYC, OCT4, KLF4 and/or LIN28 [37].
In parallel, improvements in cardiac differentiation
protocols have increased efficiency from 1% to 98%
(reviewed previously in [21]). This has been achieved
by identifying signalling pathways that sequentially
regulate key steps in cardiac development in vivo,
including pathways involving transforming growth
factor family members (TGF-; bone morphogenetic
proteins [BMP] and Activin A), fibroblast growth fac-
tors (bFGF; FGF2) and Wingless (WNT). Translating
these developmental signals to hiPSCs in vitro has
been empirical and iterative but has defined the con-
centrations and timings of growth factors and/or small
molecules that activate or inhibit relevant cardiogenic
pathways. Thus, the relative ease of efficient repro-
gramming and directed cardiogenesis is accelerating
progress towards biomedical application.
hiPSCs capture genome diversity
The ability to efficiently produce hiPSC-CMs rep-
resents an essential development to model human
cardiac disease. This technology is now being cou-
pled with advances in precise genome engineering.
This allows the introduction or correction of almost
any mutation of interest [38] and overcomes the
issues of cost, time and species differences associ-
ated with the generation and study of animal models
for the myriad of patient mutations. In addition, it
enables the study of mutations in the unique genetic
environment of the individual patient, allowing for
genome-mutation interactions to be revealed.
Initially, genetic modification of human pluripo-
tent stem cells (hPSCs) was challenging but the
improvements in culture systems allowed transfec-
tion and viral transduction efficiencies of >50% and
314 S. Kalra et al. / hiPSC-CM Models for Muscular Dystrophies
95%, respectively [39]. Additionally, low recom-
bination frequencies (1 in 106–109 cells) in most
mammalian cells prevented widespread take-up of
gene targeting. With the advent of nuclease-mediated
approaches including zinc finger nucleases [40, 41]
and transcription activator-like effector nucleases
[42, 43] improved the targeting efficiencies by up
to 2000- fold. However, the greatest breakthrough in
genome engineering came with the development of
the Cas9/CRISPR (Clustered Regularly Interspaced
Short Palindromic Repeat) system [44]. This allowed
correction of individual patient mutations to cre-
ate isogenic controls in which only the mutated
sequences differ in an otherwise unchanged genetic
background. Conversely, it is also possible to intro-
duce different genetic mutations in a control hiPSC
lines, allowing the study of mutation-specific effects
in a controlled genetic environment. Kim et al. [45]
showed up to 79% targeting efficiency in CCR5 locus
in human cells, including human embryonic stem
cells (hESCs). The efficiency of the approach is at the
level that projects are underway to knock out every
gene in the mouse genome; it is likely that similar
projects will follow in hPSCs. Therefore, hiPSCs are
ideally positioned for personalised medicine, but can
in theory also facilitate the study and identification of
disease modifiers [2].
hiPSCs for drug development and toxicology
studies
In the 13 years from 2000–2013, pharmacolog-
ical responses of hiPSC-CMs to only 60 different
compounds had been demonstrated [18] but sin-
gle reports now evaluate over 130 compounds [46].
Assessment by AstraZeneca [47], J&J [48] and
GlaxoSmithKline [49] have shown that hiPSC-CMs
can detect cardiotoxicity at an accuracy of 70–90%
and rival predictivity of primary cells isolated from
dog and rabbit hearts [50]. Notably, hiPSC-CMs were
used to show that toxicity was reduced when the
anticancer drug, doxorubicin, was delivered via a
HER2-targeted liposomal pathway; this assisted the
decision to advance to Phase I testing [51]. Such
studies have led the CIPA initiative (Comprehensive
In Vitro Proarrhythmia Assay) to propose integration
of hiPSC-CMs into the ICH (International Confer-
ence on Harmonisation) S7a/b and E14 guidelines
by the end of 2015. These guidelines have been the
mainstay over the last decade of preclinical assess-
ment of cardiac electrophysiology for new drugs
[52]. These observations have continued into pheno-
typic and pharmacological assessment of hiPSC-CM
models of various conditions [18]. This includes
the disorders that affect electrophysiology, struc-
ture, contractility and survival (see below and refs:
[53–64]. Most notably, the inability to manage effec-
tively treatment of an individual with complex LQTS
was addressed by deriving hiPSC-CMs and per-
forming multi-parameter in vitro drug testing to
better define the underlying molecular defect and
test responses to two alternative clinical strategies
[65]. This approach allowed for a pre-emptive ex-vivo
risk/efficacy assessment of available clinical strate-
gies for management of cardiac disease in a complex
patient, demonstrating the utility of hiPSCs for per-
sonalised medicine.
MODELING DILATED
CARDIOMYOPATHY: DMD CASE STUDY
Brief overview of DCM in DMD
DCM is a prevalent cardiac manifestation in MDs
with cardiac involvement (Table 1). It is characterized
by progressive left ventricular dilation, fibrosis, and
defects in CM contractile properties. Cardiac moni-
toring and management in the clinic are similar for all
forms of MDs with DCM (reviewed in [4, 66]). Here,
we will focus on DMD as a case study to illustrate
advantages and challenges associated with hiPSCs in
modelling DCM.
In DMD patients, cardiac disease is of early onset
and by 20 years of age almost 100% of patients
show cardiac involvement. Hor et al. studied 314
DMD patients using magnetic resonance imaging
and detected cardiac fibrosis in 17% of patients <10
years of age and in 34% of patients <15 years of age
[15]. As the disease progresses, fibrotic tissue grad-
ually spreads and results in loss of contractility and
DCM which is characterised by left ventricular (LV)
dysfunction, thinning of LV wall, impaired diastolic
and systolic function, leaky heart walls and often
results in mitral valve regurgitation [67]. Markham
and colleagues have shown signs of LV relaxation and
decreased ventricular compliance via echocardiogra-
phy in DMD patients <15years old [68]. Myocardial
remodelling is a complex process that involves patho-
logical cross-talk among various cell types, including
fibroblasts, CMs, immune cells, and vascular cells.
This process would be difficult to recapitulate in a
dish with pure CMs. However, animal studies sug-
gest that it is a secondary event to abnormalities that
occur at the CM level (see below) and could therefore
be captured in hiPSC cultures.
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In addition to tissue remodelling typical of DCM,
cardiac involvement in DMD is also associated with
ECG abnormalities that include increased R-to-S
ratio (≥1) in lead V1, tall R waves, deep Q waves
in lead 1, arrhythmias, shorter PR interval and pro-
longed QT interval [69, 70]. While no studies have
been done so far on hiPSC-CMs from DMD patients
that recapitulate these abnormal features in the dish,
hiPSC-CMs have been used successfully to model
long QT syndrome and arrhythmias in vitro [71–76].
Therefore, it is technically possible to study ECG
abnormalities in cultured CMs from patient-derived
hiPSCs.
Molecular mechanisms of cardiac disease
in DMD
In DMD, frameshifting or nonsense mutations
in the DMD gene cause loss of expression of a
functional dystrophin protein in all striated muscles
[77]. Dystrophin performs both structural and less
well characterized signalling functions. The primary
structural role of dystrophin is to link the intracel-
lular sub-membranous actin network to laminin in
the extracellular matrix via the transmembrane and
extracellular members of the dystrophin-associated
protein complex (DAPC). Loss of dystrophin expres-
sion in DMD, leads to a severe reduction of the
DAPC at the muscle cell membrane. This disruption
of the structural functions of the DAPC leads to mem-
brane fragility in the face of repeated contractions
and increased membrane permeability, accompanied
by impaired calcium buffering and increased oxida-
tive stress. These imbalances ultimately predispose
muscle cells to necrosis. While this structural model
is well validated in skeletal muscles, it does not com-
pletely fit with the current observations in cardiac
muscle.
The structural components of the DAPC comprise
dystrophin, - and -dystroglycans, -, -, δ-, and
-sarcoglycans, and laminin [78]. Mutations in the
genes encoding for these proteins invariably lead to
MDs. Furthermore, glycosylation of -dystroglycan
is essential for its binding to laminin and is critical
for function. Thus, mutations in enzymes involved
in the complex glycosylation of -dystroglycan are
associated with MDs [79, 80]. If disruption in any
of these proteins destabilizes the DAPC and compro-
mises its structural functions, it would be expected
that cardiac disease would be present in all related
MDs and would show similar underlying molecular
defects. However, this is not the case. In particular,
mutations in laminin 2 cause severe skeletal muscle
disease but are rarely associated with cardiac disease
in MDC1A patients [81, 82]. If cardiac disease is
present, it is usually mild. This observation could
suggest that laminin (specifically laminin 2) is not
the primary extracellular ligand of -dystroglycan
in the heart. Other extracellular ligands have been
identified for-dystroglycan. For most of them, bind-
ing appears to require -dystroglycan glycosylation
[83]. It would therefore be expected that mutations
in enzymes that glycosylate dystroglycan would dis-
rupt multiple ligand interactions and therefore lead
to DCM. However, among all identified enzymes
that affect the glycosylation of -dystroglycan and
lead to severe skeletal muscle disease, only mutations
in two of them, Fukutin and Fukutin related pro-
tein, are associated with DCM (Table 1). This raises
the interesting possibility that -dystroglycan binds
to different extracellular matrix proteins in cardiac
versus skeletal muscle with differential involve-
ment of its core protein and carbohydrates moieties.
How ligand binding affects the functions, struc-
tural or otherwise of -dystroglycan is currently
unknown.
A second intriguing observation is that membrane
integrity is not severely compromised in CMs in
the dystrophin-deficient mdx mouse. In contrast to
skeletal muscle fibres, increased membrane perme-
ability to vital dyes is primarily observed in mdx CMs
after strenuous exercise or challenge with adrenergic
agonists [84, 85]. Therefore, additional mechanisms
must be in place to attenuate the damaging effects
of the loss of dystrophin on membrane integrity
in CMs, compared to skeletal muscle myofibres.
This is supported by a growing body of evidence
indicating progressive intracellular elevation of cal-
cium in dystrophin-deficient CMs via perturbation
in ion channel function, rather than a catastrophic
rise in intracellular calcium associated with mem-
brane tearing [86–88]. Finally, in MDs associated
with mutations in - or δ-sarcoglycans, mechanisms
extrinsic to CMs have been shown to contribute to
DCM in mouse models [89]. These studies have
implicated smooth muscle defects leading to arterial
constrictions that cause regional ischemia as contrib-
utors to CM death. A similar pathological mechanism
is not observed in DMD and associated animal mod-
els. Therefore, although many of the MDs listed in
Table 1 involve proteins that are part of the DAPC,
DCM does not necessarily arise from identical under-
lying molecular and cellular defects, with potential
implication for treatment responses.
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Furthermore, experiments by our group have
recently revealed key differences in the protein
composition of the DAPC between cardiac and skele-
tal muscles in the mouse [90]. Interestingly, we
reported that most differences involve the intracel-
lular binding partners of dystrophin, -dystrobrevin,
syntrophins, and neuronal nitric oxide synthase
(nNOS). These proteins are involved in the less char-
acterized signalling functions of dystrophin; these
include mechanotransduction, nitric oxide signalling,
clustering of membrane and extracellular matrix
proteins, and regulation of ion channels, calcium
homeostasis, cell survival, and membrane targeting
of proteins [91–99]. We also reported novel cardiac-
specific associations of dystrophin with four proteins
involved in cardiac disease: Cavin-1 (PTRF), -B-
crystallin, Cypher (LDB3, ZASP) and Ahnak1 [90].
The functional significance of these differences in
DAPC composition between cardiac and skeletal
muscles is currently under investigation.
Taken together, these observations highlight gaps
in our knowledge of the molecular underpinnings of
cardiac disease in DMD and in related MDs involving
the DAPC. Modelling these diseases in a dish using
patient-derived hiPSCs offers unique opportunities to
contrast and compare disease triggers in CMs. This is
critically important to determine whether DCM asso-
ciated with different DAPC-related mutations is truly
one disease and one treatment can fit all.
What disease parameters can be studied
in hiPSC-CMs?
Developmental progression of disease
and correlation with genetic mutation
The DMD gene is extremely complex. It con-
tains 7 different promoters with tissue-specific and
developmentally regulated expression patterns. They
encode 3 full length transcripts that contain all 79
exons leading to 420 kDa proteins, as well as shorter
protein isoforms with different N-termini that vary
in size from 260 kDa (Dp260) to 71 kDa (Dp71).
The functional significance of this complex pattern
of isoform expression and switching during matura-
tion is not well understood. Differentiation of hESCs
into CMs was used to show that isoform Dp71b was
expressed in both undifferentiated and differentiated
cells, whereas Dp140 and the long muscle-specific
isoform, Dp427m, were expressed only upon the
onset of CM differentiation [100]. These studies sug-
gest that multiple dystrophin isoforms are expressed
during maturation of human CMs, although these
findings need to be confirmed in a more homoge-
neous culture system. The possible implication is that
depending on the location of the mutation along the
DMD gene, it could abrogate expression of one or
multiple dystrophin isoforms, with potentially differ-
ent consequences for CM maturation and function.
The availability of newer monolayer differentiation
protocols that produce high purity hiPSC-CMs and
the demonstration that specific CM subtypes can
now be produced will allow a better understanding
the developmental expression of dystrophin isoforms
[21]. This opens the door to detailed studies of the
effects of different mutations along the DMD gene
on CM ultrastructure and contractile parameters.
Membrane fragility and calcium handling
Of the functional consequences of the muscu-
lar dystrophies, calcium handling is best studied in
hPSC-derivatives. Aberrant handling in DMD is typ-
ified by increased intracellular calcium and abnormal
calcium sparks, particularly in response to contrac-
tion and stress [87, 101–103]. The underlying causes
have not been elucidated and mechanisms may dif-
fer between different forms of MDs. In DMD, two
hypotheses have been advanced with respect to the
cause of increased intracellular calcium. The first
postulates that loss of dystrophin causes membrane
fragility leading to membrane tears that facilitate cal-
cium influx. However, there is no direct evidence to
support this hypothesis in the heart. The best indirect
evidence is the observation that membrane sealants
such as Poloxamer P188 can normalize intracellular
calcium levels in dystrophin-deficient mouse car-
diac myocytes [53]. The second proposes that loss
of dystrophin disrupts either directly or indirectly
the regulation of ion channels that regulate calcium
homeostasis in the heart. In support of this hypothe-
sis, elevated intracellular calcium has been reported
in resting CMs and appears to be in part associated
with increased expression of stretch activated recep-
tors [102].
DMD hiPSC-CMs could be extremely useful in
testing the relative contribution of these two dif-
ferent hypotheses to elevated intracellular calcium
during differentiation and CM maturation. Past stud-
ies give credence to the potential use of hiPSC-CMs
in such an investigation. Models using hiPSC-CMs
have been produced for LQTS8 / Timothy Syn-
drome (mutations in the ICa-L calcium channel;
[104] and catecholaminergic polymorphic ventricu-
lar tachycardia-1 (CPVT1; mutations in ryanodine
receptor; RYR2; [71, 105, 106]. In CPVT1
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hiPSC-CMs, dantrolene was shown to abolish
isoprenaline-induced arrhythmias [71]. In addition,
the use of calcium assays in hiPSC-CMs is becom-
ing commonplace due to the ease and availability
of high speed / resolution optical mapping tech-
niques. Typically, this uses voltage-sensitive dyes
(e.g. ANEPPS) [107] or genetically-encoded volt-
age indicators [108] to measure action potentials and
calcium wave propagation. Indeed, Guan and co-
workers showed a two-fold increase in T50 (duration
of recovery) of Ca2+ transients in DMD hiPSC-
CMs compared to healthy hiPSC-CMs. Although this
is in agreement with data from other model sys-
tems investigating skeletal muscle [109–111], only
one DMD hiPSC line was studied and a more
detail investigation is needed. In this regard, Lin and
co-workers examined a collection of DMD, BMD
(Becker Muscular Dystrophy) and healthy hiPSC-
CMs. This included demonstration that treatment for
7 days with the membrane sealant, Poloxamer P188,
could reduce both caspase-3 activation and apopto-
sis in the DMD hiPSC-CMs. In particular, staining
of the treated DMD hiPSC-CMs with the Ca2+ sen-
sitive dye, Rhod-2AM, revealed increased cytosolic
[Ca2+]i concentration [53].
Mitochondrial function
The overload in calcium that is associated with
muscular dystrophies can lead to compromised mito-
chondrial function [112]. The utility of evaluating
mitochondrial function using the Seahorse XF Flux
analyser has been demonstrated in several hiPSC-CM
models of disease, including Barth syndrome [60],
Diabetes type I [113] and ARVD [63]. For exam-
ple, in Barth syndrome, hiPSC-CMs demonstrated
reduced ATP production and respiration capacity
[60] when exposed to sequential treatment with elec-
tron transport chain inhibitors such as oligomycin,
antimycin-A and rotenone and FCCP. However, using
DMD hiPSC-CMs, Guan and colleagues did not find
any differences in mitochondrial metabolic function
[111], which is in contrast to other studies. Thus,
in diseased hiPSC-CMs, swollen mitochondria were
observed using transmission electron microscopy,
while staining with the potentiometric dye, JC-1,
showed a ∼2.5-fold increase in the number of mito-
chondria with disrupted membrane potential [53].
Other reports show reduced oxidative phosphoryla-
tion in vitro, in vivo and in isolated mitochondria from
skeletal muscles of mdx mice or DMD patients [114,
115]. Further work is needed to understand the cause
of these differences.
Electrophysiology / E-C coupling
hiPSC-CMs have been extensively used to recapit-
ulate and study ex vivo cardiac disorders associated
with conduction defects or electrocardiogram (ECG)
abnormalities such as long QT syndrome (Reviewed
in [116]). Importantly, these studies have demon-
strated a strong correlation between results obtained
with hiPSC-CMs and primary adult human CMs.
Furthermore, they have shown that patient-derived
hiPSC-CMs can be used to predict in vivo responses
of the whole heart to drug treatments.
Currently, a variety of techniques are available
to study electrophysiology in cultured CMs ranging
from field action potentials to patch clamp record-
ings on individual ion channels (reviewed in [55]).
Abnormal ion channel function has been reported in
primary CMs from DMD mouse models. This has
been evidence by reduced inactivation kinetics of L-
type calcium channels and over-activation of stretch
activated channels in mouse models of DMD result-
ing in increased intracellular calcium concentrations
and affecting action potential kinetics [87, 102].
In addition, direct and indirect mechanisms that
affect -syntrophin and alternative splicing of -
dystrobrevin give rise to abnormal regulation of
sodium channels in myotonic dystrophy and are asso-
ciated with long QT syndrome [117–119].
In addition to direct measurement of membrane
voltage, quantification of calcium sparks and intra-
cellular calcium levels in cultured CMs is possible.
Increased intracellular calcium and abnormal cal-
cium sparks have been reported in CMs from animal
models of neuromuscular disorders both in response
to contraction and following stress [87, 102, 103,
120, 121]. Increased intracellular calcium has been
linked to mitochondrial dysfunction and structural
abnormalities in dystrophic CMs, predisposing to
apoptotic cell death. To date, limited studies have
been performed on hiPSC-CMs from DMD patients
(Table 2). The current data show impaired calcium
handling similar to CMs derived from animal models
and indicate a similar role in impaired mitochon-
drial function and apoptosis [53, 111]. These early
studies also demonstrate that hiPSCs derived from
DMD patients can generate atrial, ventricular and
nodal CMs [111]. This offers the possibility to study
the effects of underlying genetic mutations on the
electrophysiological properties of each of these CM
sub-types at a level of cellular and sub-cellular res-
olution that cannot be achieved in vivo. Therefore,
hiPSCs represent a powerful tool to model conduc-
tion and ECG defects associated with MDs at the
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level of the individual patient. Future use of these
cells to assess electrophysiology will be informative
in a system that more accurately reflects the com-
plexity of protein splice variants, the heterogeneity
of underlying genetic mutations and the electrophys-
iological properties of the human heart compared to
animal models.
Structural/sarcomeric abnormalities
Imaging has also been used to investigate dif-
ferences between healthy hiPSC-CMs relative to
DMD hiPSC-CMs or engineered DMD knock out
hiPSC-CMs. Whereas healthy hiPSC-CMs have an
aspect ratio (length: width) of ∼5, the value is
∼3.8 for dystrophic hiPSC-CMs. The dystrophic
CMs also showed significant increase in cell surface
area compared to healthy CMs, which corresponded
to reduced actin turnover. These observations may
explain the reduced ability of dystrophic hiPSC-CMs
to respond to environmental cues, including the nano-
topography of the substrate [122].
Myocardial contractility and function
There are several aspects of myocardial dysfunc-
tion that are commonly observed in MDs. At the level
of the whole myocardium, deficits in force produc-
tion, a blunted response to adrenergic stimulation,
and progressive ventricular dilation are commonly
observed. Only relatively recently has contraction
force been measured in hiPSC-CMs. This shows that
twitch forces are in the 2-260nN range for single
hiPSC-CMs [123–125] and 0.08–4.4 mN/mm2 range
for 3D engineered heart tissue (EHTs) derived from
hiPSC-CMs [126]. The impact of different drugs
on hiPSC-CM contractility has also been measured.
Impedance-based have been used to test a panel
of 49 cardioactive compounds on hiPSC-CM. The
sensitivity, specificity and accuracy was reported as
90%, 74%, and 82%, respectively, which compared
favourably when compared to in vitro data for dog
(83%, 84% and 82%) and rat (77%, 74%, and 74%)
CMs [127]. EHTs made from rat, mouse, and human
CMs have differences in the maximal twitch forces
(0.22, 0.05, and 0.08mN) and sensitivity to exter-
nal Ca2+ (EC50:0.15, 0.39, and 1.05 mM Ca2+)
[128].
DMD hiPSC-CMs carrying an exon 45 deletion
(described previously [111]) and isogenic DMD
knockout hiPSC-CMs have high contraction velocity
of 10–20m/s relative to 5–7m/s in healthy CMs.
Furthermore, healthy hiPSC-CMs on nano-patterns
showed greater anisotropic contractions whereas high
variability in contraction direction was seen in DMD
hiPSC-CMs [122].
MODELING CONDUCTION SYSTEM
DEFECTS (CSDS): DM1 CASE STUDY
Brief overview of cardiac disease with CSDs
CSDs are a predominant feature of cardiac disease
in myotonic dystrophies and in MDs with mutations
in nuclear proteins (e.g. Emery-Dreyfuss muscu-
lar dystrophies; limb-girdle muscular dystrophy 1B;
Table 1). CSDs can occur alone or in associa-
tion with DCM. In general, management involves
pharmacological and device based (implantation of
pacemakers or defibrillators) interventions (reviewed
in [66, 129]). DM1 cardiac pathology commonly
involves tachyarrhythmias and defects in conduction
systems due to degeneration, fibrosis and fatty infil-
tration, and, less often, myocardial dysfunction and
ischemia. Conduction abnormality is mainly char-
acterised by defects in sinus node, atrio-ventricular
node and His-Purkinje system, and is mostly associ-
ated with prolonged PR interval, QRS duration and
His bundle to ventricle (HV) interval [130]. 65%
of DM1 patients exhibit abnormal ECG patterns,
which include first degree AV block (42%), right
(3%) and left (4%) bundle branch block respectively
and intraventricular conduction delay (12%) [131].
DM1 patients also suffer from risk of developing
bundle branch tachycardia and atrial arrhythmias, fib-
rillation and flutter, are common. Echocardiographic
abnormalities include mitral valve prolapse, systolic
and diastolic function impairment, and reduction in
ejection fraction [130]. Current cardiac management
includes pharmacological interventions and device
implantation [129].
Current knowledge of disease mechanisms
DM1 is due to unstable expansion of CTG trinu-
cleotides in 3’-UTR of the DMPK gene [132], which
is considered to form a stem loop regulated by RNA
binding proteins. Numerous mechanisms that cre-
ate diverse phenotypic effects have been previously
proposed [133]. In brief, accumulation of expanded
mRNA in DM1 cells, also referred to as foci, is
considered as hallmark feature of DM1, which medi-
ate RNA gain-of function. Accumulating foci cause
muscleblind-like (MBNL) protein sequestration, as
well as concurrent activation and increased expres-
sion of CELF1 [134, 135]. Both MBNL and CELF1
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regulate splicing, with aberrant function altering pro-
file of cardiac troponin T, muscle-specific chloride
channel and sarcoplasmic/endoplasmic reticulum
Ca2+ ATPase1 [136–138]. Alternatively, depletion
of MBNL has shown to perturb (i) alternative
polyadenylation in mouse embryo fibroblasts, skele-
tal muscle in transgenic mouse DM1 model and
DM1 patients; (ii) regulation of mRNA localisation;
(iii) regulation of mRNA transcription and transla-
tion [139, 140]. MBNL1 may also regulate miR-1
microRNA biogenesis, acting via the LIN28 pathway,
which could cause aberration of calcium channels and
gap junctions, hence explain some of the abnormal
cardiac function seen in DM1 patients [141]. Mutant
RNA repeats are also suggested to play role in other
RNA binding proteins such as Staufen1 and Dead
box RNA helicases, which regulate protein transla-
tion [142, 143]. Additional hypotheses exist which
supports the role of expanded CTG repeats in trigger-
ing hypermethylation of rRNA promoters, inhibition
of rRNA transcription [144], and disruption of other
cellular processes including repeats associated non-
ATG (RAN) translation [145] and antisense DMPK
transcription [146, 147].
What disease parameters can be studied
in hiPSC-CMs?
Developmental progression
A high degree of repeat instability can occur
between different somatic tissues and during
transmission from DM1 parents to children, a phe-
nomenon known as genetic anticipation. However,
the mechanism(s) by which this occurs are limited
(reviewed in [148–150]) and DM1 hPSC models
could provide insights. Several reports have shown
instability during the reprogramming process or
during culture of DM1 hPSCs but not in differ-
entiated cells, including osteogenic progenitor cells
[151–153]. Nevertheless, these observations contra-
dict in vivo data where CTG repeats are unstable
during oocyte development but stable in zygote and
embryo [154, 155]. Additionally, no repeat instability
was observed in the 13 week-old human DM1 foe-
tus, although heterogeneity did occur by 16 weeks
of gestation [156, 157]. The reason for these dif-
ferences will need to be resolved before the value
of DM1 hiPSCs can be determined but may relate
to differences in species or (epi) genetics. Other
influencing parameters such as starting repeat length
or differentiated cell types assessed could be eval-
uated using the hiPSC model, particularly when
compared to corrected isogenic controls produced by
gene targeting. Developing such data would provide
the foundation with which to evaluate the ability of
new therapeutics to inhibit repeat expansion.
Understanding and restoring gene function
Understanding gene function and evaluating the
impact of potential therapeutic interventions is the
area of research that has received the most attention
in the DMD and DM1 hPSC field (Tables 2 & 3).
For example, DM1 is characterised by improper gene
expression and methylation. Yanovsky-Dagan and
co-workers studied 14 different DM1-hESC lines
and showed that hypermethylation occurred upstream
of CTG repeats when repeat number exceeded 300
[158]. The process of reprogramming patient fibrob-
lasts into hiPSCs resulted in hypermethylation but
was not associated with an expansion in the repeat
size. The authors of that study also went on to show
that there was a negative correlation between methy-
lation and expression of neighbouring gene, SIX5, but
no correlation of DMPK expression in DM1 hESCs
and DM1 hESC-CMs [158].
The RNA gain of function mechanism in DM1 sug-
gests that CUG repeats induce symptoms of DM1
by altering the function of CUG-binding splice reg-
ulating proteins, including MBNL1 and CUGBP1.
The over-expression of human CUGBP1 adult mouse
heart has shown to reproduce functional and molec-
ular abnormalities of DM1 [159]. Recently, cardiac
phenotypes and MBNL sequestration has been stud-
ied using a Drosophila model expressing expanded
repeats under cardiac-specific promoter GMH5-Gal4
[160]. So far, such events have only been investi-
gated in non-CM lineages from hPSCs (Table 3).
Xia and co-workers showed presence of RNA foci
in cells from all three germ layers derived from
DM1-hiPSCs [161]. Similarly, PGD-derived DM1-
hESC lines [162] differentiated into neural stem
cells showed formation of RNA foci along with
decreased proliferation and increased autophagy.
This model also offered the opportunity to evaluate
potential genetic interventions, both to shed mech-
anistic insight to DM1 and to evaluate potential
treatments. Thus, involvement of MBNL1 in mTOR
signalling was demonstrated by siRNA knockdown
[163], while a targeted approach positioned poly
A signals upstream of CTG repeats in the DMPK
gene by TALEN-mediated genome engineering in
DM1 hiPSC-derived neural stem cells. The latter pre-
vented production of CUG expanded transcripts and
restored healthy phenotype, as gauged by loss of RNA
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foci, increased expression of microtubule-associated
protein tau (MAPT) and decreased expression of
MBNL1 & 2 [164]. Nevertheless, TALENs targeted
both the healthy and mutated allele, whereas a thera-
peutic would have to modify only the mutated DM1
allele [164].
Small molecules are also being considered as
potential therapeutics for reduction of RNA foci in
DM1. A medium throughput phenotypic assay in
patient-derived fibroblast and myoblast cells was
used to screen a total of ∼16,000 compounds from
a Chembridge Diverset, NPC and Enzo Life Sci-
ences libraries. This identified the protein kinase C
inhibitor, Ro 31-8220, as being able to reduce and/or
remove nuclear foci [165]. For hiPSC-CMs, imaging
and particularly high content imaging is now becom-
ing commonplace to examine subcellular structures,
which will be important to investigate the resolution
of RNA foci in DM1. In addition to validating the
efficacy of drugs such as Ro 31-8220, the hiPSC-CM
system will be useful in evaluating potential car-
diotoxicity, which is well established issue associated
with kinase inhibitors [166]. Thus, Mioulane and
co-workers [167] triggered cell stress with the cell-
permeable protein kinase C inhibitor, chelerythrine.
Combining stains for TMRM (a potentiometric dye;
tetramethylrhodamine methyl ester), caspase-3 or
BOBO-1 with Cellomics Arrayscan imaging, they
assessed mitochondrial function, apoptosis and cell
death, respectively and demonstrated that hPSC-CMs
are less susceptible to chelerythine-stimulated apop-
tosis compared to rat neonatal ventricular CMs. In an
impressive study, Sirenko and colleagues [168] used
CalceinAM, Hoechst and MitoTracker imaging on
the ImageXpress Micro to evaluate cardiotoxicity of
131 modulators of Na+, K+ and Ca2+ channels, as
well as adreno-, dopamine- and histamine-receptors
on CDI iCell hiPSC-CMs in a 384-well format.
Calcium handling
Several studies have reported altered Ca2+ han-
dling in DM1 muscles, DM1 myotubes and DM1
mouse models [169–171]. More recently, aberrant
splicing affecting a number of channels (such as
SERCA1, RyR1 and CACN1S) is thought to be
involved in altered Ca2+ signalling in DM1-affected
muscles. For example, exon 29 of the CACN1S
gene is abnormally skipped in DM1 patients. Induc-
ing exon 29 skipping in wild type mice leads to
increased Ca2+ channel conductance and voltage sen-
sitivity, thus affecting EC coupling [172]. Enhanced
skipping of CACN1S exon 29 in the DM1 mouse
model exacerbates muscle pathology and better mir-
rors disease severity seen in DM1 patients [172]. The
combined effect of mis-spliced SERCA1, RyR1 and
CACN1S genes is increased EC coupling, as well as
altered Ca2+ release and uptake from SR. This is
likely to cause chronic Ca2+ accumulation, a com-
mon phenomenon thought to occur in MD. More
recent studies using microarrays on DM1 patients
identified Ca2+ signalling as the most significantly
affected pathway, showing upregulation of 14% of
genes involved in Ca2+ release, uptake, storage, or
signalling [173]. Differential splicing ofCACN1S has
been demonstrated in DM1 mouse and human mod-
els. However, the difference could be attributed to
various factors including species difference in splice
regulation, difference in repeat expansion in mod-
els studied or difference in RNA flanking the CTG
repeat [172]. Some of the listed limitations can be
overcome by using isogenic hiPSC lines to study the
mutation-specific effect in a genetically controlled
environment.
Mitochondrial function
In humans, four out of seven DMPK isoforms
anchor into the outer mitochondrial membrane or
endoplasmic reticulum, indicating a role for DMPK
in mitochondrial dysfunction. Elevated expression
levels of the mutated DMPKA isoform is impli-
cated in numerous cell changes, as determined
from studies using a range of cell lines, and heart
and skeletal muscle of transgenic mice. These
changes include perinuclear clustering, abnormal
mitochondrial ultrastructure, decreased mitochon-
drial membrane potential and release of cytochrome
C, which lead to apoptosis [174, 175]. Recently it
has been reported that alternative splicing causes
increased expression of pyruvate kinase M2 in DM1
skeletal and heart tissue. This results in increased
glucose consumption but decreased oxidative phos-
phorylation, suggesting that the energy production
is less efficient in DM1 cells [176]. Mitochondrial
function studies have already been successful in hiP-
SCs derived from Barth syndrome [60] and diabetic
patients [113], which gives confidence that in vivo
changes in bioenergetics could be recapitulated in
DM1 hiPSC-CMs.
Electrophysiology/ EC coupling and contractility
With the increased awareness of cardiac involve-
ment in muscular dystrophies, there is a concomitant
increase in publications on Holter, ECG and MRI
studies. These show that 90% of DMD patients show
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cardiac involvement as the disease progresses. In
the case of DM1, a pan-European registry identi-
fied the PR interval of 29% patients was >200msecs
on the electrocardiogram, while 46% experienced
arrhythmia or conduction block, of which 37% had
a cardiac implant (pacemaker or implantable car-
dioverter defibrillator) [177].
For DM1, cardiac conduction defects and altered
contractility have been observed in DMPK−/−
knockout mice and isolated human primary DM1
CMs [178–180], which parallels the observations
made in the hearts of DM1 patients. More recently,
prevalence of Brugada type 1 ECG pattern have been
reported in DM1 patients, implicating the role of Bru-
gada syndrome in tachyarrhythmias and cardiac death
[181, 182]. The cardiac electrical and contractile phe-
notype of DM1 has been studied using a mouse
model; this constitutively expresses the human DM1
locus under the regulation of its own promoter and
cis-regulatory elements, after flecainide treatment
[183]. The altered INa in this mouse model was sug-
gested to be the cause of reduced cellular excitability
[183]. Furthermore, function and localisation of Cl−
channel (PLM) is also modulated by DMPK, suggest-
ing that DMPK is involved in EC coupling in muscle
cells [184]. The loss of DMPK in knockout mice
has been shown to enhance the basal contractility of
single CMs concurrent with an associated increase
in intracellular calcium during systole, suggesting
role of DMPK in control of calcium homeostasis
[120]. Furthermore, reduced expression of miR-1
microRNA in DM1 patient hearts has been reported to
alter the regulation of connexion 43 and CACNA1C,
which may contribute to the cardiac abnormalities
observed in affected patients [141]. Although, these
parameters have not yet been examined in DM1
hiPSC-CMs, they have been successfully studied in
other cardiac diseases as discussed above (see section
on electrophysiology and myocardial contractility in
DMD).
OPPORTUNITIES AND CHALLENGES
In recent years there has been considerable
progress in the culture, differentiation technologies
and genetic modifications associated with hiPSC-
CMs. Nevertheless, this is still a nascent technology
and there are still considerable challenges to be over-
come. There is a need for: 1) standardisation of
reprogramming methods (viral vs non-viral/ integrat-
ing vs non-integrating) as it can affect the genome
and epigenome; 2) introduction of standards on how
to select good quality cell lines that should be used
for screening and disease modelling; 3) determination
of the number of cell lines per patient that need to be
generated to control for variations arising from differ-
ences in reprogramming; 4) optimization of protocols
to improve reproducibility and robustness of cardiac
differentiation in order to allow translation from basic
research laboratories to industrial and biomedical
platforms.
Limited maturation occurs in hiPSC-CMs, which
is consistent with mid-gestation of human foetal
heart development. This is evidenced by examin-
ing 30 or so parameters that are used to quantify
CMs, including structure, gene expression, amount
of sarcoplasmic reticulum, metabolism, mitochon-
dria location and number, electrophysiology, calcium
handling and contractility [21]. Thus, while hiPSC-
CMs are functional and already have proven utility in
drug and disease valuation, all phenotypes might not
be fully recapitulated. Thus, there is not only a need
for careful interpretation of data relative to appropri-
ate (e.g. isogenic) controls, but also an appreciation
of the current limitations of the model. For example,
immature hiPSC-CMs lack well-developed T-tubule
system and show action potential and calcium param-
eters similar to embryonic heart, making it difficult to
study the distribution and function of dystrophin in
hiPSC-CMs. We have previously shown a diffused
pattern of dystrophin in hiPSC-CMs [100], which
contrasts to the defined membrane localisation pat-
tern in adult skeletal and heart muscle [185]. Clarity
will also be required on details such as whether all the
components of DAPC are present, correctly localised
and functional in immature CMs. Naturally there are
major efforts to address maturity in the knowledge
that each incremental improvement could make a
considerable difference to the utility of the models
produced. Indeed, many investigators are evaluating
physical, chemical, genetic and environmental induc-
ers to facilitate maturation (reviewed in detail in [21,
186, 187]). It will be interesting to see if the abnor-
mal expression of embryonic splicing of MBNL and
CUGBP (discussed above) is maintained in DM1
hiPSC-CMs and if maturation of CMs has any effect
on this.
Although large scale differentiation can produce
hiPSC-CMs at purities of >80%, the cultures are
heterogeneous with a mixture of ventricular, atrial
and pacemaker subtypes. The quality of data pro-
duced would likely be enhanced if single subtypes
could be isolated. Until recently, reliable methods to
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isolate subtypes remained elusive. However, there
have been recent exciting developments. Birket and
colleagues [188] combined a complex but elegant
double transgenic approach, wherein an NKX2.5-
GFP targeted hESC line was further transfected with
an inducible MYC expression construct. In the pres-
ence of insulin-like growth factor-1 (IGF-1) and a
hedgehog pathway agonist, cardiovascular progeni-
tor cells could be isolated and proliferated for over 40
population doublings. Moreover, modulating exoge-
nous BMP, FGF, WNT and RA signalling led to
multi-lineage differentiation, as well as directed spec-
ification to pacemaker and ventricular cells. This
report was remarkable because it not only showed
long-term proliferation of hPSC-derived cardiac pro-
genitors (in 11 other reports using mouse and human
PSCs, maximum expansion was 4-fold) [189], but it
was the first robust demonstration of subtype spec-
ification. In an alternative approach, modulation of
retinoic acid signalling during hESC differentiation
was used to generate atrial- and ventricular-like CMs.
These CM subtypes were used to show that the multi-
ion channel blocker, vernakalant, and Kv1.5 blocker,
XEN-D0101, caused a reduction in early repolariza-
tion only in the atrial cells [190], providing a novel
preclinical test platform for these drug classes.
As explained above, the breath of approaches to
phenotype cell is expanding with a greater reliance
on high content platforms, which will increase the
throughput available. However, to confirm the pheno-
type and evaluate the significance of what is observed
in culture, parallel studies in vivo are important, but
lacking. The DMD and DM1 hiPSC-CM models that
have been generated so far have predominantly relied
on cells cultured in 2D on tissue culture plastic. This
represents a rather simple model compared to the
complex 3D architecture of the intact heart, wherein
there is a combination of CMs, cardiac fibroblasts,
endothelial cells and smooth muscle cells that expe-
rience continuous contractile and haemodynamic
forces. It has already been shown that combining
hiPSC-CMs with vascular and/or fibroblastic cells
can improve function [191, 192]. Further work is
needed to determine whether engineering complex
tissue and organ models can improve the hiPSC-CM
models to create unique disease models for studying
multifaceted phenotypes in certain MD.
The potential of permanent genetic correction
is rising to the fore with the advent of nuclease-
mediated gene targeting approaches and proof of
principle studies have been conducted in hPSC mod-
els [193–197]. For example, TALENs have been
shown to allow correction of DMD hiPSC-derived
skeletal muscle cells carrying deletion in exon 44
via frameshift, exon skipping and exon knock-in
approaches [196]. In other DMD studies, TALENs
and ZFNs have been shown to enhance expression
of dystrophin by correcting the mutation ( exon
48–50) in DMD-derived myoblasts by correcting
the reading frames [198, 199]. TALEN-mediated
genome engineering has enabled poly A signals to be
positioned upstream of CTG repeats in DM1 hiPSC-
derived neural stem cells to prevent expression of
mutant DMPK transcripts. However, there are no
reports of direct correction of theDMPKgene in DM1
hPSCs. This is likely to be due to the highly repetitive
and complex nature of the repeat region, which may
interfere with the targeting strategy. Such difficulties
may be overcome with high efficiency Cas9/CRISPR
approaches.
More controversially, genome engineering raises
the possibility of correcting mutations in the
germline, fertilised egg or early stage embryo and the
first attempts to use this technology have been made.
The Cas9/CRISPR system was used in a somewhat
abortive and controversial [200] attempt to target the
-globin gene in human embryos. However, the effi-
ciency of targeting was low (14%), edited embryos
were mosaic and the level of off-target events was
high due to homology with delta-globin gene [201].
Earlier in Feb 2016, the first gene editing study in
human embryos has been approved and whether such
studies will more widely be given approval and if
these will be suitable for correction of DMD and
DM1 mutations remains to be seen. If they are, it is
likely small polymorphisms of a few bases that cause
premature termination would be targeted first due to
the complexity of correcting multi-intron deletions in
DMD or highly repetitive triplet repeats in DM1.
CONCLUDING REMARKS
The ability to produce hiPSC-CMs offers new
opportunities in biomedicine. Over the last 5 years
a swathe of hiPSC-CM models have been developed
for genetic conditions that affect the electrophysiol-
ogy, signalling and survival of cells within the heart.
Whereas a few years ago, evaluating a few drugs
for cardiotoxicity was a major undertaking, improve-
ments in the hiPSC-CM technology mean single
reports can now screen over 130 compounds, show-
ing acceleration in the field. Many major academic
institutes and pharmaceutical companies are now
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evaluating hiPSC-CMs, with excellent outcomes:
Refinement in patient risk stratification for sudden
cardiac death; progression of anticancer drugs to the
clinic; the first clinical trials for heart failure. Such
developments are now percolating into the muscu-
lar dystrophy field with 5 of the 10 DMD and 1 of
the 7 DM1 models investigating hiPSC-CM func-
tion. In some cases, these have been used to evaluate
corrective therapies. Nevertheless, this is a nascent
field. Alignment of large scale hiPSC banking ini-
tiatives with pan-EU initiatives (e.g. MRC BioBank,
EuroBioBank network, TREAT-NMD Network of
Excellence) for rare diseases, including DMD and
DM1, is only just starting. The potential of using
Cas9/CRISPR genome engineering technologies to
exponentially increase the diversity of mutations and
genotypes available is only now becoming reality but
may provide a way to unveil the impact on func-
tion of single nucleotide polymorphisms identified
via genome-wide association studies (GWAS). Such
studies will require methods that can assess hiPSC-
CM function in detail, whilst being sufficiently high
throughput to examine phenotype across large num-
bers of hiPSC lines or genome engineered derivatives.
As these tools are developed, there should be better
correlation of clinical pathology with in vitro pheno-
type and hence evaluation of potential therapies. This
should also help resolve debates on whether treat-
ments that have shown benefit to skeletal muscle have
a positive or negative impact in the heart. Realising
these goals will require better understanding of the
biology of hiPSC-CM maturation and subtype spec-
ification to make the models more representative of
the working heart. For each of these areas, interna-
tional efforts are underway and it can be expected
that over the next 5 years hiPSC-CMs will become
an important additional tool in muscular dystrophy
research and therapy.
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